Therapeutics: Integrin α9β1; integrin α4β1 (CD49D/CD29)

Mouse studies suggest dual inhibition of integrin α9β1 and integrin α4β1 in donors could help enhance the production of donor-derived hematopoietic stem cells (HSCs) used for BMT. In mice, a dual inhibitor of integrins α9β1 and α4β1 increased the mobilization of endosteal HSCs and bone marrow progenitor cells into the peripheral blood compared with vehicle. In a mouse model of BMT, peripheral blood from healthy donors pretreated with the inhibitor increased recipient survival compared with blood from donors pretreated with Mozobil plerixafor. Next steps include preclinical toxicity studies of an undisclosed dual inhibitor of integrin α9β1 and integrin α4β1...